DE60326223D1 - Verbindungen mit affinität zum 5ht2c-rezeptor und deren therapeutische verwendung - Google Patents
Verbindungen mit affinität zum 5ht2c-rezeptor und deren therapeutische verwendungInfo
- Publication number
- DE60326223D1 DE60326223D1 DE60326223T DE60326223T DE60326223D1 DE 60326223 D1 DE60326223 D1 DE 60326223D1 DE 60326223 T DE60326223 T DE 60326223T DE 60326223 T DE60326223 T DE 60326223T DE 60326223 D1 DE60326223 D1 DE 60326223D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- alkyl
- alkoxy
- haloc
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0209029A GB0209029D0 (en) | 2002-04-19 | 2002-04-19 | Compounds |
GB0220781A GB0220781D0 (en) | 2002-09-06 | 2002-09-06 | Compounds |
PCT/EP2003/004180 WO2003089409A1 (fr) | 2002-04-19 | 2003-04-17 | Composes presentant une affinite avec le recepteur 5ht2c et utilisation therapeutique de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60326223D1 true DE60326223D1 (de) | 2009-04-02 |
Family
ID=29252459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60326223T Expired - Fee Related DE60326223D1 (de) | 2002-04-19 | 2003-04-17 | Verbindungen mit affinität zum 5ht2c-rezeptor und deren therapeutische verwendung |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050203079A1 (fr) |
EP (1) | EP1497265B1 (fr) |
JP (1) | JP2005529117A (fr) |
AT (1) | ATE423094T1 (fr) |
AU (1) | AU2003222832A1 (fr) |
DE (1) | DE60326223D1 (fr) |
WO (1) | WO2003089409A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
GB0305024D0 (en) * | 2003-03-05 | 2003-04-09 | Glaxo Group Ltd | Compounds |
GB0305553D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Compounds |
EP2248524A3 (fr) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci |
EP2742936A1 (fr) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique condensé et son utilisation |
WO2008128919A2 (fr) * | 2007-04-19 | 2008-10-30 | Ucb Pharma S.A. | Composés comprenant un groupe cyclobutoxy |
EP2789338A3 (fr) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Dérivé de pyridine condensé et son utilisation |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
EP3733204A4 (fr) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale |
CA3121202A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composes pyrrole et pyrazole et leurs procedes d'utilisation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9612885D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
EP1113015B1 (fr) * | 1999-12-29 | 2004-09-15 | Pfizer Products Inc. | Dérivés de 3-((2-pipérazinyl-phényle)méthyle)-1-(4-(trifluorométhyl)-phényl)-2-pyrrolidinone optiquement actifs utilisés en tant qu'antagonistes sélectifs du recepteurs de 5-HT 1D |
ES2320973T3 (es) * | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
GB0305024D0 (en) * | 2003-03-05 | 2003-04-09 | Glaxo Group Ltd | Compounds |
-
2003
- 2003-04-17 JP JP2003586130A patent/JP2005529117A/ja active Pending
- 2003-04-17 EP EP03718783A patent/EP1497265B1/fr not_active Expired - Lifetime
- 2003-04-17 DE DE60326223T patent/DE60326223D1/de not_active Expired - Fee Related
- 2003-04-17 AT AT03718783T patent/ATE423094T1/de not_active IP Right Cessation
- 2003-04-17 AU AU2003222832A patent/AU2003222832A1/en not_active Abandoned
- 2003-04-17 US US10/511,769 patent/US20050203079A1/en not_active Abandoned
- 2003-04-17 WO PCT/EP2003/004180 patent/WO2003089409A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ATE423094T1 (de) | 2009-03-15 |
US20050203079A1 (en) | 2005-09-15 |
EP1497265B1 (fr) | 2009-02-18 |
AU2003222832A1 (en) | 2003-11-03 |
EP1497265A1 (fr) | 2005-01-19 |
JP2005529117A (ja) | 2005-09-29 |
WO2003089409A1 (fr) | 2003-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004003927D1 (de) | Verbindungen mit aktivität am 5ht2c-rezeptor und anwendungen davon | |
AU2021204985B2 (en) | Compositions and methods of modulating 15-pgdh activity | |
PT1797099E (pt) | Compostos de piperidinilamino-tieno[2,3-d]pirimidina | |
ATE423094T1 (de) | Verbindungen mit affinität zum 5ht2c-rezeptor und deren therapeutische verwendung | |
HRP20090454T1 (hr) | Derivati pirazola kao inhibitori receptorskih tirozin kinaza | |
NO20050417L (no) | Azaindol kinase-inhibitorer | |
RU2002110461A (ru) | Производные хиназолина и их применение в качестве фармацевтических веществ | |
ATE360004T1 (de) | Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften | |
FI893634A0 (fi) | Menetelmä valmistaa terapeuttisesti aktiivisia mono- tai disubstituoituja (imidatsol-4-yyli)metyylipyrido/4,3-b/indol- ja atsepino/4,3-b/indol-1-oneja | |
DE602004012842D1 (de) | An 5ht2c-rezeptor aktive verbindungen und ihre verwendungen | |
US20140357654A1 (en) | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | |
NZ227685A (en) | 5,6,7,8-tetrahydrobenzo(b)thieno(2,3-b)pyridine derivatives and pharmaceutical compositions | |
CA2523253C (fr) | Methyle indoles et methyle pyrrolopyridines servant d'agonistes du recepteur adrenergique alpha-1 | |
NZ501785A (en) | 4-(3,4-dihydro-2-naphthylmethyl)- or 4-(2H-3-chromenylmethyl)-4,5-dihydro-1H-imidazole derivatives | |
HUP0101311A1 (hu) | 3-Szubsztituált 3,4,5,7-tetrahidro-pirrolo[3',4':4,5]tieno[2,3-d]pirimidin-származékok, eljárás előállításukra és alkalmazásuk 5-HT antagonistákként | |
PL1776339T3 (pl) | Pochodne 3-(((-4-fenylo)-piperazyn-1-ylo)-alkilo)-3-alkilo-1,3-dihydro-2H-indol-2-onu i związki pokrewne do leczenia chorób centralnego układu nerwowego | |
ATE323085T1 (de) | Heterozyclische verbindungen mit affinität für den ht1 rezeptor und ihre therapeutische verwendung | |
HU0103912D0 (en) | Use of substituted alkylpyridazinone derivatives for the preparation of pharmaceutical compositions with anxiolytic activity | |
AU2003233793A1 (en) | Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | |
WO2003106444A8 (fr) | Diazocycloalcanes n,n-disubstitues utiles dans le traitement de troubles du systeme nerveux central dus a un dysfonctionnement serotoninergique | |
WO2006061373A3 (fr) | Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |